Reviewed clinical summary · Source-linked · Educational use only

Low-Carb vs Mediterranean Diet and Bone Turnover Markers in Young Type 1 Diabetes: A Null Result

Hormone Insight visual abstract summarising low-carb versus Mediterranean diet and bone turnover in type 1 diabetes.
Visual abstract for low-carb versus Mediterranean diet in type 1 diabetes.

Clinical Bottom Line

A 24-week RCT finds neither a low-carbohydrate nor a Mediterranean diet significantly changes bone turnover markers in young people with type 1 diabetes, an exploratory null result. PICO summary and commentary.

Summary: In a 24-week trial in adolescents and young adults with type 1 diabetes, neither a low-carbohydrate nor a Mediterranean diet produced significant changes in bone turnover markers, with the differences between diets not statistically significant in this exploratory analysis.

PICO Summary

ElementDetail
Population40 individuals aged 12–21 with type 1 diabetes (20 per group); 24-week randomised controlled trial, Israel.
InterventionA low-carbohydrate diet (median 86 g carbohydrate/day).
ComparisonA Mediterranean diet (median 130 g carbohydrate/day).
OutcomeBone turnover markers did not change significantly: CTX went from 395 to 423 pg/mL on low-carb (p=0.278) and 357 to 296 on Mediterranean (p=0.245); P1NP changes were also non-significant (p=0.056 and p=0.594). Lower calcium and magnesium intake and BMI z-score on low-carb did not survive false-discovery-rate correction. Only adjusted alkaline phosphatase fell significantly in the low-carb group (p=0.009). The authors concluded differences were insignificant.
RCT Nutrients · 2025

Low-carb vs Mediterranean diet and bone turnover in type 1 diabetes

RCT · type 1 diabetes · 24 weeks

Trial design
T1D, aged 12–21 (n=40) Enrolled & assessed RANDOMISED 1:1 Low-carb Median 86 g carb/day n = 20 Mediterranean Median 130 g carb/day n = 20 Change in CTX (bone resorption marker)
Change from baseline — both arms
CTX (pg/mL) Baseline Week 24 Low-carb +28; Mediterranean -61 (both NS) Low-carb Mediterranean
CTX low-carb
395→423 pg/mL
p=0.278 (NS)
CTX Mediterranean
357→296 pg/mL
p=0.245 (NS)
P1NP change
Non-significant
p=0.056 / 0.594
Between-diet difference
Not significant
Exploratory
⬡ Bottom Line

Over 24 weeks neither diet significantly changed bone turnover markers (CTX or P1NP), and between-diet differences were not significant. An exploratory null result offering qualified reassurance, not evidence the diets differ for bone.

Expert Commentary

This is an exploratory study whose honest result is reassurance through a null finding, and it must be read that way rather than as evidence that the diets differ for bone. The question matters, because type 1 diabetes carries excess fracture risk that emerges early, adolescence is the window of peak bone-mass accrual, and low-carbohydrate diets raise theoretical concerns about acid load and reduced calcium intake. Against that backdrop, the key message is that over 24 weeks neither diet significantly changed the bone resorption marker CTX or the formation marker P1NP, and the apparent between-diet differences in mineral intake and BMI did not survive correction for multiple comparisons. The lone significant signal, a fall in alkaline phosphatase on low-carb, is of uncertain meaning. Limitations reinforce caution in both directions: only 20 per group, surrogate turnover markers rather than bone density or fractures, and just 24 weeks. Can I use this with my patients? Yes, as qualified reassurance. For a young person with type 1 diabetes choosing a low-carbohydrate diet for glycaemic reasons, this provides some short-term comfort that bone turnover was not adversely disturbed, while I would still ensure adequate calcium and vitamin D and recognise that longer studies with density and fracture endpoints are needed before firm conclusions.

References

Levran N, Levek N, Levy-Shraga Y, et al. Bone turnover markers (CTX and P1NP) following low-carbohydrate and Mediterranean diet interventions in adolescents and young adults with type 1 diabetes. Nutrients. 2025;17(24):3935. doi:10.3390/nu17243935

Educational use: Hormone Insight is intended for healthcare professionals and learners. Interpret each summary alongside the primary source, local guidance, and patient-specific clinical judgement.

Subscribe now

Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.

© 2024-2026 Hormone Insight. All rights reserved.